Previous 10 | Next 10 |
Arcturus Therapeutics (NASDAQ: ARCT ) has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering of 850,000 common shares at $11.50/share, for gross proceeds of ~$9.8M. More news on: Arcturus Therapeutics Holdings...
SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of mRNA therapeutics for rare diseases, today announced that it has ente...
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced ...
The following slide deck was published by Arcturus Therapeutics Holdings Inc. in conjunction with this Read more ...
SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced t...
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2019 Results Conference Call August 15, 2019 04:30 PM ET Company Participants Neda Safarzadeh - Head, IR Joseph Payne - President and CEO Andy Sassine - CFO Dr. Pad Chivukula - Chief Scientific Officer and COO Conference Call Par...
Arcturus Therapeutics (NASDAQ: ARCT ): Q2 GAAP EPS of -$0.07. Revenue of $10.15M (+324.7% Y/Y) Press Release More news on: Arcturus Therapeutics Holdings Inc, Earnings news and commentary, Healthcare stocks news, ,
Ultragenyx Pharmaceutical, Inc. expands collaboration, becoming Arcturus’ largest shareholder Cystic Fibrosis Foundation increases commitment to $15 million Arcturus receives Orphan Drug Designation from the U.S. FDA for ARCT-810 Conference call and audio webcast at 4:30 PM ET to...
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a co...
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has entered in...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...